MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers
Panelists discuss how successful academic-community partnerships in delivering chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma patients have evolved through shared learning experiences, established communication pathways, and continuous refinement of collaborative care protocols.
Video content above is prompted by the following:
- Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR T-cell therapy for multiple myeloma?
- Dr Usmani to ask Dr Mailankody: What are the most important lessons your institution has learned in the integration of CAR T therapy into the multiple myeloma treatment landscape?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
